von Willebrand factor 1,000unit powder and solvent for solution for injection vials
Requires a prescription from a doctor or prescriber
The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for von Willebrand factor on the MHRA register
Willfact 1,000unit powder and solvent for solution for injection vials
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)
Heavy menstrual bleeding: assessment and management (NG88)
Intrapartum care (NG235)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 15 · 1995–2020
Showing all 30 studies, sorted by most relevant.
F. Gragnano, S. Sperlongano, E. Golia, et al.
Mediators of Inflammation, 2017
- ADAMTS13 Protein
- Inflammation
- von Willebrand Factor
Beyond its role in hemostasis, von Willebrand factor (VWF) is an emerging mediator of vascular inflammation. Recent studies highlight the involvement of VWF and its regulator, ADAMTS13, in mechanisms that underlie vascular inflammation and immunothrombosis, like leukocyte rolling, adhesion, and extravasation; vascular permeability; ischemia/reperfusion injury; complements activation; and NETosis. The VWF/ADAMTS13 axis is implicated in the pathogenesis of atherosclerosis, promoting plaque formation and inflammation through macrophage and neutrophil recruitment in inflamed lesions. Moreover, VWF and ADAMTS13 have been recently proposed as prognostic biomarkers in cardiovascular, metabolic, and inflammatory diseases, such as diabetes, stroke, myocardial infarction, and sepsis. All these features make VWF an attractive therapeutic target in thromboinflammation. Several lines of research have recently investigated "tailor-made" inhibitors of VWF. Results from animal models and clinical studies support the potent anti-inflammatory and antithrombotic effect of VWF antagonism, providing reassuring data on its safety profile. This review describes the role of VWF in vascular inflammation "from bench to bedside" and provides an updated overview of the drugs that can directly interfere with the VWF/ADAMTS13 axis.
Abstract licence: CC BY
C. Kawecki, P. Lenting, Cécile V. Denis
Journal of Thrombosis and Haemostasis, 2017
- Inflammation
- ADAMTS13 Protein
- Blood Platelets
Junmei Chen, D. Chung
Blood, 2018
- ADAMTS13 Protein
- Blood Platelets
- Gene Expression Regulation
A. Randi, Koval E Smith, G. Castaman
Blood, 2018
- Blood Vessels
- Endothelium, Vascular
- Gene Expression Regulation
A. Randi, M. Laffan
Journal of Thrombosis and Haemostasis, 2017
- Blood Coagulation
- Blood Platelets
- Glycoproteins
Fred E. Cohen, S. B. Prusiner, D. G. Hardie, et al.
Annual review of biochemistry, 1998
- Coagulants
- von Willebrand Factor
- von Willebrand Diseases
J. Sadler, U. Budde, J. Eikenboom, et al.
Journal of Thrombosis and Haemostasis, 2006
- ADAMTS13 Protein
- Models, Biological
- Phenotype
P. Lenting, O. Christophe, C. Denis
Blood, 2015
- Cysteine
- Glycosylation
- Half-Life
I. Mancini, L. Baronciani, A. Artoni, et al.
Journal of Thrombosis and Haemostasis, 2020
- Blood Coagulation
- ADAMTS13 Protein
- COVID-19
Hongxia Fu, Yan Jiang, Darren Yang, et al.
Nature Communications, 2017
- Hemostasis
- Algorithms
- Hemorrhage
Von Willebrand factor, an ultralarge concatemeric blood protein, must bind to platelet GPIbα during bleeding to mediate hemostasis, but not in the normal circulation to avoid thrombosis. Von Willebrand factor is proposed to be mechanically activated by flow, but the mechanism remains unclear. Using microfluidics with single-molecule imaging, we simultaneously monitored reversible Von Willebrand factor extension and binding to GPIbα under flow. We show that Von Willebrand factor is activated through a two-step conformational transition: first, elongation from compact to linear form, and subsequently, a tension-dependent local transition to a state with high affinity for GPIbα. High-affinity sites develop only in upstream regions of VWF where tension exceeds ~21 pN and depend upon electrostatic interactions. Re-compaction of Von Willebrand factor is accelerated by intramolecular interactions and increases GPIbα dissociation rate. This mechanism enables VWF to be locally activated by hydrodynamic force in hemorrhage and rapidly deactivated downstream, providing a paradigm for hierarchical mechano-regulation of receptor-ligand binding.Von Willebrand factor (VWF) is a blood protein involved in clotting and is proposed to be activated by flow, but the mechanism is unknown. Here the authors show that VWF is first converted from a compact to linear form by flow, and is subsequently activated to bind GPIbα in a tension-dependent manner.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Clotting factor VIII or coagulation factor VIII is a glycoprotein involved in th…
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
Protein binding
[L40049]
Volume of distribution
69.7 mL
[A32270]
Metabolism
[A32262]…
Elimination
[A32266]…
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
It is also indicated for on-demand treatment and perioperative management of bleeding in pediatric patients with VWD, and for routine prophylaxis to reduce the frequency of bleeding episodes in adults with VWD (including Types 1 and 2)[L40049]
In combination with [antihemophilic factor human], vWF is also used to manage and control bleeding associated with von Willebrand disease in children and adults, as well as for perioperative management of bleeding in these patients. This combination product is also used for the management and control of bleeding episodes in adolescents and adults with hemophilia A, as well as for routine prophylaxis to reduce the frequency of bleeding episodes.
[L1878]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 92 interactions
Both coagulation factor VIII and vWF are essential blood clotting factors in normal hemostasis; however, certain blood disorders such as hemophilia A and von Willebrand disease are associated with reduced or deficient levels of functional clotting factors. Reduced levels of vWF in plasma lead to decreased levels and activity of factor VIII, and abnormal platelet function, thereby resulting in excessive bleeding.[L1878] Exogenous sources of human vWD aim to restore the levels of vWF in circulation to control and prevent bleeding episodes in patients with the reduced capability of blood clotting. Exogenous vWF treatment is also available as a combination product also containing exogenous coagulation factor VIII to replenish the levels of both clotting factors.[L1878]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L40049]
[L40049]
[L40049]
[A32270]
[A32262]
Proteolysis of vWF occurs primarily in the cleavage site at domain A2, which is a target domain for ADAMTS13.
[A32290]
[A32266]
[L40049]
Proteins and enzymes this drug interacts with in the body
The receptor then returns to the cell membrane surface
PMID:11907044 PMID:12713657
Required for early embryonic development (By similarity). Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors.
Acts as an LRPAP1 alpha-2-macroglobulin receptor .
PMID:1702392 PMID:26142438
Acts as TAU/MAPT receptor and controls the endocytosis of TAU/MAPT as well as its subsequent spread .
PMID:32296178
May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission .
PMID:12888553
Also acts as a receptor for IGFBP3 to mediate cell growth inhibition PMID:9252371
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC B02BD06
ATC B02BD10
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Von Willebrand factor human
Matched from: von Willebrand factor
Additional database identifiers
Drugs Product Database (DPD)
13371
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3546
GenAtlas
F8
GeneCards
F8
GenBank Gene Database
M14113
GenBank Protein Database
182818
UniProt Accession
FA8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2197
GenAtlas
COL1A1
GeneCards
COL1A1
GenBank Gene Database
Z74615
GenBank Protein Database
1418928
UniProt Accession
CO1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:742
GeneCards
ASGR1
UniProt Accession
ASGR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6692
GenAtlas
LRP1
GeneCards
LRP1
GenBank Gene Database
X13916
GenBank Protein Database
34339
UniProt Accession
LRP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1366
GeneCards
ADAMTS13
UniProt Accession
ATS13_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q96414099), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.